Jonathan R. Day

Jonathan R. Day

Auto-generated profile, based on publicly available information

Jonathan R. Day

Department of Internal Medicine University of Iowa Carver College of Medicine Iowa City Iowa USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2022 in Haemophilia
Verified
Journal Article
Open access
JDJonathan R. Day
Jonathan R. Day
CTClifford Takemoto
Clifford Takemoto
ASAnjali Sharathkumar
Anjali Sharathkumar
SMSarah Makhani
Sarah Makhani
AGAshwin Gupta
Ashwin Gupta
RGRuchika Goel
Ruchika Goel
Introduction: Current in‐hospital burden and healthcare utilization patterns for persons with haemophilia (PWH) A and B, including both children (ages < 18 years) and adults (ages ≥ 18 years), in the United States (US) are lacking.Aim: To evaluate healthcare utilization, the prevalence of comorbidities, and mortality in hospitalized paediatric and adult PWH using a contemporary nationally representative cohort.Methods: Hospitalizations of PWH either as the primary reason for admission (principal diagnosis) or one of all listed diagnoses were identified using ICD‐10 codes from the 2017 Nationwide Inpatient Sample (NIS), the largest publicly available all‐payer inpatient discharge database in the US. Sampling weights were applied to generate nationally representative estimates.Results: The contemporary cohort included 10,555 hospitalizations (paediatrics, 18.3%; adults, 81.7%) among PWH as one‐of‐all listed diagnoses (n = 1465 as principal diagnosis). Median age (interquartile range) was 46 (24–66) years overall; adults, 54 (35–70) years and paediatric, 4 (1–11). The most common comorbidities in adults were hypertension (33.4%), hyperlipidaemia (23.6%), and diabetes (21.1%). In children, hemarthrosis (11.4%), contusions (9.6%), and central line infections (9.3%) were the most common. The overall mortality rate was 2.3%. Median hospital charges per haemophilia admission were $52,616 ($24,303–$135,814) compared to $26,841 ($12,969–$54,568) for all‐cause admissions in NIS.Conclusion: Bleeding and catheter‐related infections are the significant reasons for paediatric haemophilia admissions. Adult haemophilia admissions tend to be associated with age‐related comorbidities. Costs for haemophilia‐related hospitalizations are higher than the national average for all‐cause hospitalizations.

9 November 2026 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
AAAhmed L. Al-Mashhadi
Ahmed L. Al-Mashhadi
MSMikkel R. Simonsen
Mikkel R. Simonsen
ESElizabeth Smyth
Elizabeth Smyth
RARose Marie Amini
Rose Marie Amini
BABente Arboe
Bente Arboe
TETarec C. El-Galaly
Tarec C. El-Galaly
Splenic Marginal Zone Lymphoma (SMZL) is an indolent non-Hodgkin lymphoma subtype. Due to its rarity, evaluation of real-world data is necessary to inform clinical practice. In this study, adults diagnosed with SMZL between 2000 and 2018 from North America, Europe, and Australia were included and followed until death or last visit. Data were extracted from medical records and regional/national registries. In total, 987 patients with median age of 68 years were included. The 10-year overall survival (OS) estimates were 59% (95%CI: 55-63) from first-line treatment and 49% (95%CI: 43-57) from second-line treatment. First-line splenectomy (n = 434) and rituximab monotherapy (n = 121) were associated with an Inverse Probability of Treatment Weighting (IPTW)-adjusted 5-year failure-free survival (FFS) of 52% for splenectomy versus 42% for rituximab; HR 0.70 (95%CI: 0.44-1.13) and adjusted HR for OS of 1.09 (95%CI: 0.59-2.01). The 10-year cumulative risk of transformation from diagnosis was 15% (95%CI: 12-18) with 5-year post-transformation OS of 38% (95%CI: 29-49), and 23% (95%CI: 13-41) for transformation after previous chemotherapy. Lower rates of transformation were seen in patients receiving frontline rituximab. While frontline therapy with either splenectomy or rituximab monotherapy had similarly favorable outcomes, patients had a persistent risk of progression and transformation andsurvival after transformation was poor.